Find Ribociclib manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

106RELATED EXCIPIENT COMPANIES

173EXCIPIENTS BY APPLICATIONS

PATENTS & EXCLUSIVITIES

0

Health Canada Patents

API REF. PRICE (USD/KG)

$
$ 0
API/FDF Prices: Book a Demo to
explore the features and consider
upgrading later

MARKET PLACE

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Weekly News Recap #Phispers

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: Lee011 succinate, 1374639-75-4, Lee-011 succinate, Lee011-bba, Ribociclib succinate [usan], Kisqali
Molecular Formula
C27H36N8O5
Molecular Weight
552.6  g/mol
InChI Key
NHANOMFABJQAAH-UHFFFAOYSA-N
FDA UNII
BG7HLX2919

Ribociclib
1 2D Structure

Ribociclib

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
butanedioic acid;7-cyclopentyl-N,N-dimethyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrrolo[2,3-d]pyrimidine-6-carboxamide
2.1.2 InChI
InChI=1S/C23H30N8O.C4H6O4/c1-29(2)22(32)19-13-16-14-26-23(28-21(16)31(19)17-5-3-4-6-17)27-20-8-7-18(15-25-20)30-11-9-24-10-12-30;5-3(6)1-2-4(7)8/h7-8,13-15,17,24H,3-6,9-12H2,1-2H3,(H,25,26,27,28);1-2H2,(H,5,6)(H,7,8)
2.1.3 InChI Key
NHANOMFABJQAAH-UHFFFAOYSA-N
2.1.4 Canonical SMILES
CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5.C(CC(=O)O)C(=O)O
2.2 Other Identifiers
2.2.1 UNII
BG7HLX2919
2.3 Synonyms
2.3.1 MeSH Synonyms

1. Kisqali

2. Lee011

3. Ribociclib

2.3.2 Depositor-Supplied Synonyms

1. Lee011 Succinate

2. 1374639-75-4

3. Lee-011 Succinate

4. Lee011-bba

5. Ribociclib Succinate [usan]

6. Kisqali

7. Lee-011-bba

8. Bg7hlx2919

9. 7-cyclopentyl-n,n-dimethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxamide Succinate

10. Butanedioic Acid;7-cyclopentyl-n,n-dimethyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrrolo[2,3-d]pyrimidine-6-carboxamide

11. Ribociclib Succinate (usan)

12. Butanedioic Acid, Compd. With 7-cyclopentyl-n,n-dimethyl-2-((5-(1-piperazinyl)-2-pyridinyl)amino)-7h-pyrrolo(2,3-d)pyrimidine-6-carboxamide (1:1)

13. Butanedioic Acid, Compd. With 7-cyclopentyl-n,n-dimethyl-2-[[5-(1-piperazinyl)-2-pyridinyl]amino]-7h-pyrrolo[2,3-d]pyrimidine-6-carboxamide (1:1)

14. Unii-bg7hlx2919

15. Kisqali (tn)

16. Lee011 (succinate)

17. Birociclib [who-dd]

18. Schembl2684999

19. Chembl3707266

20. Ribociclib Succinate [mi]

21. Dtxsid301027923

22. Amy25508

23. Bcp12715

24. Ex-a1586

25. Zec63975

26. Lee011 Succinatelee011 Succinate

27. Hy-15777b

28. S5188

29. Ribociclib Succinate [who-dd]

30. Sb18482

31. Ac-30654

32. As-75241

33. Ribociclib Succinate [orange Book]

34. D10979

35. Lee-011 Succinate Salt, Ribociclib Succinate Salt

36. J-007026

37. Q27274660

38. Kisqali Femara Co-pack Component Ribociclib Succinate

39. Ribociclib Succinate Component Of Kisqali Femara Co-pack

40. 7-cyclopentyl-n,n-dimethyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}-7h-pyrrolo[2,3-d]pyrimidine-6-carboxamide; Butanedioic Acid

2.4 Create Date
2012-06-20
3 Chemical and Physical Properties
Molecular Weight 552.6 g/mol
Molecular Formula C27H36N8O5
Hydrogen Bond Donor Count4
Hydrogen Bond Acceptor Count11
Rotatable Bond Count8
Exact Mass552.28086628 g/mol
Monoisotopic Mass552.28086628 g/mol
Topological Polar Surface Area166 Ų
Heavy Atom Count40
Formal Charge0
Complexity728
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count2
4 Drug and Medication Information
4.1 Drug Information
1 of 2  
Drug NameKISQALI
Active IngredientRIBOCICLIB SUCCINATE
CompanyNOVARTIS PHARMS CORP (Application Number: N209092. Patents: 8324225, 8415355, 8685980, 8962630, 9193732, 9416136, 9868739)

2 of 2  
Drug NameKISQALI FEMARA CO-PACK (COPACKAGED)
Active IngredientLETROZOLE; RIBOCICLIB SUCCINATE
CompanyNOVARTIS PHARMS CORP (Application Number: N209935. Patents: 8324225, 8415355, 8685980, 8962630, 9193732, 9416136, 9868739)

4.2 Drug Indication

Kisqali is indicated for the treatment of women with hormone receptor (HR)positive, human epidermal growth factor receptor 2 (HER2)negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy.

In pre or perimenopausal women, the endocrine therapy should be combined with a luteinising hormonereleasing hormone (LHRH) agonist.


5 Pharmacology and Biochemistry
5.1 ATC Code

L01XE


API SUPPLIERS

read-more
read-more

01

Egis Pharmaceuticals PLC

Hungary

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothEgis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

Flag Hungary
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Egis Pharmaceuticals

02

Suanfarma

Spain

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothSuanfarma, at the Core of a Better Life.

Flag Spain
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Suanfarma

03

Aarti Pharmalabs

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothAarti Pharmalabs is a partner of choice for APIs & Intermediates and the largest Indian manufacturer of Xanthine Derivatives.

Flag India
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Aarti Industries Company Banner

04

Chunghwa Chemical Synthesis & Biot...

Taiwan

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothChunghwa provides cost-effective APIs & advanced intermediates with complete DMF or COS, ensuring quality & reliable production.

Flag Taiwan
Digital Content Digital Content
USDMF arrow-down CEP/COS JDMF EU-WC NDC arrow-down KDMF VMF Others AUDIT
CCSB Company Banner

05

TAPI Technology & API Services

Israel

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothTAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.

Flag Israel
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
TAPI Company Banner

06

Chunghwa Chemical Synthesis & Biot...

Taiwan

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothChunghwa provides cost-effective APIs & advanced intermediates with complete DMF or COS, ensuring quality & reliable production.

Flag Taiwan
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC arrow-down KDMF VMF Others AUDIT
CCSB Company Banner

07

Teva Pharmaceutical Industries

Israel

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

AACR Annual meeting
Not Confirmed
arrow

Teva Pharmaceutical Industries

Israel

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
AACR Annual meeting
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

08

MSN Laboratories

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

AACR Annual meeting
Not Confirmed
arrow

MSN Laboratories

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
AACR Annual meeting
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WCarrow-down NDC arrow-down KDMF VMF Others AUDIT
blank

09

Intas Pharmaceuticals

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

AACR Annual meeting
Not Confirmed
arrow

Intas Pharmaceuticals

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
AACR Annual meeting
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

10

Fresenius Kabi Oncology Limited

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

AACR Annual meeting
Not Confirmed
arrow

Fresenius Kabi Oncology Limited

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
AACR Annual meeting
Not Confirmed
USDMF Inactive-api CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

USDMF

read-more
read-moreread-more

01

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothChunghwa provides cost-effective APIs & advanced intermediates with complete DMF or COS, ensuring quality & reliable production.

Flag Taiwan
Digital Content Digital Content

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 36174

Submission : 2021-11-30

Status : Active

Type : II

CCSB Company Banner

02

AACR Annual meeting
Not Confirmed

03

AACR Annual meeting
Not Confirmed

03

AACR Annual meeting
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 35027

Submission : 2020-09-10

Status : Inactive

Type : II

blank

04

AACR Annual meeting
Not Confirmed

04

AACR Annual meeting
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2021-11-18

Pay. Date : 2021-09-24

DMF Number : 36335

Submission : 2021-09-30

Status : Active

Type : II

blank

05

AACR Annual meeting
Not Confirmed

05

AACR Annual meeting
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2020-11-03

Pay. Date : 2020-09-25

DMF Number : 35098

Submission : 2020-09-01

Status : Active

Type : II

blank

06

Tapi Nl Bv

Israel

USDMF

arrow
AACR Annual meeting
Not Confirmed

06

Tapi Nl Bv

Israel
arrow
AACR Annual meeting
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2021-01-22

Pay. Date : 2020-10-09

DMF Number : 35288

Submission : 2020-11-26

Status : Active

Type : II

blank

07

Valary Lab Private Ltd

Country

USDMF

arrow
AACR Annual meeting
Not Confirmed

07

Valary Lab Private Ltd

Country
arrow
AACR Annual meeting
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 41424

Submission : 2025-03-14

Status : Active

Type : II

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Australia

read-more
read-more

01

Novartis Pharmaceuticals Australia Pty L...

Country
AACR Annual meeting
Not Confirmed
arrow

Novartis Pharmaceuticals Australia Pty L...

Country
arrow
AACR Annual meeting
Not Confirmed

Ribociclib

Brand Name : Kisqali

Dosage Form :

Dosage Strength :

Packaging : 21

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Australia

blank

02

Novartis Pharmaceuticals Australia Pty L...

Country
AACR Annual meeting
Not Confirmed
arrow

Novartis Pharmaceuticals Australia Pty L...

Country
arrow
AACR Annual meeting
Not Confirmed

Ribociclib

Brand Name : Kisqali

Dosage Form :

Dosage Strength :

Packaging : 63

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Australia

blank

03

Novartis Pharmaceuticals Australia Pty L...

Country
AACR Annual meeting
Not Confirmed
arrow

Novartis Pharmaceuticals Australia Pty L...

Country
arrow
AACR Annual meeting
Not Confirmed

Ribociclib

Brand Name : Kisqali

Dosage Form :

Dosage Strength :

Packaging : 42

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Australia

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Listed Dossiers

read-more
read-more

01

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothEgis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

Flag Hungary
Digital Content Digital Content

Regulatory Info :

Registration Country : Hungary

Ribociclib

Brand Name :

Dosage Form : Tablet

Dosage Strength : 200MG

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Hungary

Egis Pharmaceuticals

01

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothEgis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

Flag Hungary
Digital Content Digital Content

Packaging :

Regulatory Info :

Ribociclib

Dosage : Tablet

Dosage Strength : 200MG

Brand Name :

Approval Date :

Application Number :

Registration Country : Hungary

Egis Pharmaceuticals
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Related Excipient Companies

Upload your portfolio for free, ask us

Excipients by Applications

Click here to find the perfect excipient manufacturers by their capabilities

Fillers, Diluents & Binders

read-more
read-more

Coating Systems & Additives

read-more
read-more

Thickeners and Stabilizers

read-more
read-more

Disintegrants & Superdisintegrants

read-more
read-more

Direct Compression

read-more
read-more

Lubricants & Glidants

read-more
read-more

Granulation

read-more
read-more

Controlled & Modified Release

read-more
read-more

Co-Processed Excipients

read-more
read-more

Chewable & Orodispersible Aids

read-more
read-more

Film Formers & Plasticizers

read-more
read-more

Solubilizers

read-more
read-more

Topical

read-more
read-more

Emulsifying Agents

read-more
read-more

API Stability Enhancers

read-more
read-more

Taste Masking

read-more
read-more

Coloring Agents

read-more
read-more

Rheology Modifiers

read-more
read-more

Parenteral

read-more
read-more

Digital Content read-more

Create Content with PharmaCompass, ask us

STOCK RECAP #PipelineProspector

read-more
read-more

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

US Medicaid Prescriptions

read-more
read-more

01

arrow
Iran Expo
Not Confirmed
arrow
Iran Expo
Not Confirmed

Company :

Ribociclib Succinate

Drug Cost (USD) : 166,342,358

Year : 2022

Prescribers : 2108

Prescriptions : 11958

blank

02

arrow
Iran Expo
Not Confirmed
arrow
Iran Expo
Not Confirmed

Company :

Ribociclib Succinate

Drug Cost (USD) : 119,293,640

Year : 2021

Prescribers : 1435

Prescriptions : 9277

blank

03

arrow
Iran Expo
Not Confirmed
arrow
Iran Expo
Not Confirmed

Company :

Ribociclib Succinate

Drug Cost (USD) : 128,739,776

Year : 2020

Prescribers : 1623

Prescriptions : 10654

blank

04

arrow
Iran Expo
Not Confirmed
arrow
Iran Expo
Not Confirmed

Company :

Ribociclib Succinate

Drug Cost (USD) : 91,963,508

Year : 2019

Prescribers : 1487

Prescriptions : 7989

blank

05

arrow
Iran Expo
Not Confirmed
arrow
Iran Expo
Not Confirmed

Company :

Ribociclib Succinate

Drug Cost (USD) : 56,743,154

Year : 2018

Prescribers : 1077

Prescriptions : 5264

blank

06

arrow
Iran Expo
Not Confirmed
arrow
Iran Expo
Not Confirmed

Company :

Ribociclib Succinate

Drug Cost (USD) : 24,506,783

Year : 2017

Prescribers : 672

Prescriptions : 2323

blank

07

arrow
Iran Expo
Not Confirmed
arrow
Iran Expo
Not Confirmed

Company :

Ribociclib Succinate

Drug Cost (USD) : 0

Year : 2016

Prescribers :

Prescriptions : 0

blank

08

arrow
Iran Expo
Not Confirmed
arrow
Iran Expo
Not Confirmed

Company :

Ribociclib Succinate

Drug Cost (USD) : 0

Year : 2015

Prescribers :

Prescriptions : 0

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Annual Reports

read-more
read-more

01

Brand Name : Kisqali

Ribociclib

arrow
Iran Expo
Not Confirmed

Brand Name : Kisqali

Switzerland
arrow
Iran Expo
Not Confirmed

Ribociclib

Main Therapeutic Indication : Oncology

Currency : USD

2020 Revenue in Millions : 687

2019 Revenue in Millions : 480

Growth (%) : 43

blank

02

Brand Name : Kisqali

Ribociclib

arrow
Iran Expo
Not Confirmed

Brand Name : Kisqali

Switzerland
arrow
Iran Expo
Not Confirmed

Ribociclib

Main Therapeutic Indication : Oncology

Currency : USD

2021 Revenue in Millions : 937

2020 Revenue in Millions : 687

Growth (%) : 36

blank

03

Brand Name : Kisqali

Ribociclib

arrow
Iran Expo
Not Confirmed

Brand Name : Kisqali

Switzerland
arrow
Iran Expo
Not Confirmed

Ribociclib

Main Therapeutic Indication : Oncology

Currency : USD

2022 Revenue in Millions : 1,231

2021 Revenue in Millions : 937

Growth (%) : 31

blank

04

Brand Name : Kisqali

Ribociclib

arrow
Iran Expo
Not Confirmed

Brand Name : Kisqali

Switzerland
arrow
Iran Expo
Not Confirmed

Ribociclib

Main Therapeutic Indication : Oncology

Currency : USD

2023 Revenue in Millions : 2,080

2022 Revenue in Millions : 1,231

Growth (%) : 69

blank

05

Brand Name : Kisqali

Ribociclib Succinate

arrow
Iran Expo
Not Confirmed

Brand Name : Kisqali

Switzerland
arrow
Iran Expo
Not Confirmed

Ribociclib Succinate

Main Therapeutic Indication : Oncology

Currency : USD

2017 Revenue in Millions : 76

2016 Revenue in Millions : 0

Growth (%) : New Launch

blank

06

Brand Name : Kisqali

Ribociclib Succinate

arrow
Iran Expo
Not Confirmed

Brand Name : Kisqali

Switzerland
arrow
Iran Expo
Not Confirmed

Ribociclib Succinate

Main Therapeutic Indication : Oncology

Currency : USD

2018 Revenue in Millions : 235

2017 Revenue in Millions : 76

Growth (%) : 209%

blank

07

Brand Name : Kisqali

Ribociclib

arrow
Iran Expo
Not Confirmed

Brand Name : Kisqali

Switzerland
arrow
Iran Expo
Not Confirmed

Ribociclib

Main Therapeutic Indication : Oncology

Currency : USD

2019 Revenue in Millions : 480

2018 Revenue in Millions : 235

Growth (%) : 104

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Market Place

Do you need sourcing support? Ask us

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

ABOUT THIS PAGE

Looking for 1374639-75-4 / Ribociclib API manufacturers, exporters & distributors?

Ribociclib manufacturers, exporters & distributors 1

40

PharmaCompass offers a list of Ribociclib API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Ribociclib manufacturer or Ribociclib supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Ribociclib manufacturer or Ribociclib supplier.

PharmaCompass also assists you with knowing the Ribociclib API Price utilized in the formulation of products. Ribociclib API Price is not always fixed or binding as the Ribociclib Price is obtained through a variety of data sources. The Ribociclib Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.

API | Excipient name

Ribociclib

Synonyms

Lee011 succinate, 1374639-75-4, Lee-011 succinate, Lee011-bba, Ribociclib succinate [usan], Kisqali

Cas Number

1374639-75-4

Unique Ingredient Identifier (UNII)

BG7HLX2919

Ribociclib Manufacturers

A Ribociclib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Ribociclib, including repackagers and relabelers. The FDA regulates Ribociclib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Ribociclib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Ribociclib manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

Ribociclib Suppliers

A Ribociclib supplier is an individual or a company that provides Ribociclib active pharmaceutical ingredient (API) or Ribociclib finished formulations upon request. The Ribociclib suppliers may include Ribociclib API manufacturers, exporters, distributors and traders.

click here to find a list of Ribociclib suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

Ribociclib USDMF

A Ribociclib DMF (Drug Master File) is a document detailing the whole manufacturing process of Ribociclib active pharmaceutical ingredient (API) in detail. Different forms of Ribociclib DMFs exist exist since differing nations have different regulations, such as Ribociclib USDMF, ASMF (EDMF), JDMF, CDMF, etc.

A Ribociclib DMF submitted to regulatory agencies in the US is known as a USDMF. Ribociclib USDMF includes data on Ribociclib's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Ribociclib USDMF is kept confidential to protect the manufacturer’s intellectual property.

click here to find a list of Ribociclib suppliers with USDMF on PharmaCompass.

Ribociclib KDMF

In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.

Pharmaceutical companies submit a Ribociclib Drug Master File in Korea (Ribociclib KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Ribociclib. The MFDS reviews the Ribociclib KDMF as part of the drug registration process and uses the information provided in the Ribociclib KDMF to evaluate the safety and efficacy of the drug.

After submitting a Ribociclib KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Ribociclib API can apply through the Korea Drug Master File (KDMF).

click here to find a list of Ribociclib suppliers with KDMF on PharmaCompass.

Ribociclib WC

A Ribociclib written confirmation (Ribociclib WC) is an official document issued by a regulatory agency to a Ribociclib manufacturer, verifying that the manufacturing facility of a Ribociclib active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Ribociclib APIs or Ribociclib finished pharmaceutical products to another nation, regulatory agencies frequently require a Ribociclib WC (written confirmation) as part of the regulatory process.

click here to find a list of Ribociclib suppliers with Written Confirmation (WC) on PharmaCompass.

Ribociclib NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Ribociclib as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for Ribociclib API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture Ribociclib as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain Ribociclib and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Ribociclib NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of Ribociclib suppliers with NDC on PharmaCompass.

Ribociclib GMP

Ribociclib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Ribociclib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Ribociclib GMP manufacturer or Ribociclib GMP API supplier for your needs.

Ribociclib CoA

A Ribociclib CoA (Certificate of Analysis) is a formal document that attests to Ribociclib's compliance with Ribociclib specifications and serves as a tool for batch-level quality control.

Ribociclib CoA mostly includes findings from lab analyses of a specific batch. For each Ribociclib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Ribociclib may be tested according to a variety of international standards, such as European Pharmacopoeia (Ribociclib EP), Ribociclib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Ribociclib USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty